

IO Biotech ApS

Ole Maaløes Vej 3

2200 København N

CVR No. 36474483


Annual Report 2023

9. financial year

The Annual Report was presented and adopted at the Annual General Meeting of the Company on 3 May 2024

DocuSigned by:

Mai-Britt Zocca

 Mai-Britt Zocca

CEO Signing Reason: I approve this document
Signing Time: May 3, 2024 | 2:59:32 AM PDT

A43D422215AA4E0784031DCC6F5794BA

IO Biotech ApS

Contents

Management's Statement	3
Independent Auditors' Report	4
Company Information	6
Management's Review	7
Accounting Policies	9
Income Statement	13
Balance Sheet	14
Statement of changes in Equity	16
Notes	17

Management's Statement

Today, Management has considered and adopted the Annual Report of IO Biotech ApS for the financial year 1 January 2023 - 31 December 2023.

The Annual Report is presented in accordance with the Danish Financial Statements Act.

In our opinion, the Financial Statements give a true and fair view of the assets, liabilities and financial position of the Company at 31 December 2023 and of the results of the Company's operations for the financial year 1 January 2023 - 31 December 2023.

In our opinion, the Management's Review includes a true and fair account of the matters addressed in the review.

We recommend that the Annual Report be adopted at the Annual General Meeting.

Copenhagen, 3 May 2024

Executive Board

DocuSigned by:

Mai-Britt Zocca

 Mai-Britt Zocca

CEO Signing Reason: I approve this document

Signing Time: May 3, 2024 | 2:59:32 AM PDT

A43D422215AA4E0784031DCC6F5794BA

Independent Auditors' Report

To the shareholders of IO Biotech ApS

Opinion

We have audited the financial statements of IO Biotech ApS for the financial year 1 January 2023 - 31 December 2023, which comprise income statement, balance sheet, statement of changes in equity, notes, including accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the financial position of the Company at 31 December 2023 and of the results of the Company's operations for the financial year 1 January 2023 - 31 December 2023 in accordance with the Danish Financial Statements Act.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Independence

We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code.

Management's responsibilities for the financial statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, Management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance as to whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.

As part of an audit conducted in accordance with ISAs and additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are

Independent Auditors' Report

appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.
- Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and contents of the financial statements, including the note disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Statement on the Management's review

Management is responsible for the Management's review.

Our opinion on the financial statements does not cover the Management's review, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the Management's review and, in doing so, consider whether the Management's review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether the Management's review provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, we conclude that the Management's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement of the Management's review.

Copenhagen, 3 May 2024

EY Godkendt Revisionspartnerselskab

CVR-no. 30700228



Rasmus Bloch Jespersen
State Authorised Public Accountant
mne35503

IO Biotech ApS

Company details

Company	IO Biotech ApS Ole Maaløes Vej 3 2200 København N
E-mail	info@iobiotech.com
Website	www.iobiotech.com
CVR No.	36474483
Financial year	1 January 2023 - 31 December 2023
Executive Board	Mai-Britt Zocca
Auditors	EY Godkendt Revisionspartnerselskab Dirch Passers Allé 36 2000 Frederiksberg CVR-no.: 30700228

Management's Review

The Company's principal activities

IO Biotech ApS (in the following referred to as "IO Biotech" or the "Company") is a clinical stage biotech company developing disruptive immune therapies for the treatment of cancer. IO Biotech has a pipeline of first-in-class immune modulating anti-cancer therapies based on a unique platform technology enabling the activation of T cells that are specific for immune inhibitory molecules.

IO Biotech has achieved a proven track record of progressing compounds to the clinic and has compounds in clinical development and late-stage preclinical phase.

IO Biotech has an experienced management team within immuno-oncology fields and a world-class scientific and clinical advisory board.

Unusual circumstances affecting recognition and measurement

There are no material unusual circumstances affecting recognition and measurement according to the knowledge of the management.

Development in the activities and the financial situation of the Company

Development in activities

Our product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. We believe this represents a paradigm shift in the management of cancer and that our product candidates have the potential to become cornerstones of the treatment regimens of multiple solid tumors. Our lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as Indoleamine 2,3-dioxygenase (IDO) and programmed death ligand (PD-L1). In a singlearm Phase 1/2 clinical trial of 60 patients with metastatic melanoma with the primary objective of investigating safety and tolerability, the secondary objective of investigating immunogenicity, and the tertiary objective of investigating clinical efficacy, IO102-IO103, in combination with nivolumab, demonstrated an ability to induce meaningful tumor regression and establish durable antitumor response while achieving a manageable tolerability profile for patients. The clinical efficacy endpoints in this trial included objective response (OR), progression free survival (PFS) and overall survival (OS). In this trial, we observed a confirmed overall response rate (ORR) of 73% and a complete response rate (CRR) of 50%. Based on the results from this trial, IO102- IO103, in combination with pembrolizumab, was granted BTM by the FDA for treatment of unresectable/metastatic melanoma.

Development in the financial situation

The Company's Income Statement of the financial year 1 January 2023 - 31 December 2023 shows a result of EUR -76.648.917 and the Balance Sheet at 31 December 2023 a balance sheet total of EUR 59.038.915 and an equity of EUR 18.203.452.

There is an increase in cost as there has been an increase in the activities due to moving into phase 3. Management considers the Company's financial performance in the year satisfactory and in line with the strategic directions.

In September 2023, the parent company, IO Biotech, Inc. carried out a capital increase of nominal DKK 500.000 (EUR 67.204) with total proceeds of DKK 446.400.000 (EUR 60.000.000). Of the capital increase 25%, equivalent to nominal DKK 125.000 or proceeds of DKK 111.600.000 (EUR 15.000.000) have been paid in cash and 75%, equivalent to nominal DKK 375.000 or proceeds of DKK 334.800.000 (EUR 45.000.000) is non paid share capital.

The non paid portion of the share capital must be paid upon demand by the Company's executive management. In 2022, the Company's share capital was divided in to share classes comprising A-shares, B-shares, and C-shares. In 2023, the Company made decision to close and merge the share classes into one single share class and thereby simplify the company's equity structure.

Change in Accounting Policy Concerning Presentation Currency

For the financial year 2023, the Company has changed the currency in which it presents its financial statements from Danish Kroner (DKK) to Euros (EUR). In prior financial years, the Company presented its financial statements

Management's Review

in DKK, even though its accounting records were prepared in EUR. The change in presentation currency aligns with the Company's objective to match the presentation currency to the currency of its underlying accounting records.

The change has been treated as a change in accounting policy and the comparative figures for 2023 have been restated with retrospective effect. This change in presentation currency impacts all financial statement items. As a result, all amounts previously presented in DKK are now presented in EUR.

As a consequence of the restatement, total assets, total liability, and total shareholders' equity as of December 31, 2022, previously reported at DKK 417,028 thousand, DKK 157,286 thousand, and DKK 259,742 thousand, respectively, are in these financial statements reported at EUR 55,957 thousand, EUR 21,105 thousand, and EUR 34,852 thousand, respectively. The result for the year 2022, previously reported at DKK -463,037 thousand, has been restated and reported at EUR -62,233 thousand in these financial statements. The opening equity as of January 1, 2022, previously reported at DKK 722,779 thousand, is reported at EUR 96,983 thousand.

Events after the balance sheet date

No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.

Financing and the going concern assumption

The Company is financed via shareholder's equity and payables to group enterprises. The Company has received a letter of financial support from its sole shareholder, IO Biotech, Inc., wherein IO Biotech, Inc. guarantees to support the Company with sufficient liquidity, to finance the current investment program and planned operating losses at least through 30 June 2025. On this basis, the financial statements are prepared on going concern assumption.

Accounting Policies

Reporting class

This annual report has been prepared and presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises with addition of provisions for reporting class C.

The accounting policies applied to these financial statements are consistent with those applied last year, except for the below change in currency.

Change in Accounting Policy Concerning Presentation Currency

For the financial year 2023, the Company has changed the currency in which it presents its financial statements from Danish Kroner (DKK) to Euros (EUR). In prior financial years, the Company presented its financial statements in DKK, even though its accounting records were prepared in EUR. The change in presentation currency aligns with the Company's objective to match the presentation currency to the currency of its underlying accounting records.

The change has been treated as a change in accounting policy and the comparative figures for 2023 have been restated with retrospective effect. This change in presentation currency impacts all financial statement items. As a result, all amounts previously presented in DKK are now presented in EUR.

As a consequence of the restatement, total assets, total liability, and total shareholders' equity as of December 31, 2022, previously reported at DKK 417,028 thousand, DKK 157,286 thousand, and DKK 259,742 thousand, respectively, are in these financial statements reported at EUR 55,957 thousand, EUR 21,105 thousand, and EUR 34,852 thousand, respectively. The result for the year 2022, previously reported at DKK -463,037 thousand, has been restated and reported at EUR -62,233 thousand in these financial statements. The opening equity as of January 1, 2022, previously reported at DKK 722,779 thousand, is reported at EUR 96,983 thousand.

Consolidated financial statements

Referring to section 110 of the Danish Financial Statements Act, no consolidated financial statements have been prepared. Further there is not prepared a cash flow statements as this is prepared on the group level.

Recognition and measurement

Assets are recognised in the balance sheet when it is probable as a result of a prior event that future economic benefits will flow to the Entity, and the value of the asset can be measured reliably.

Liabilities are recognised in the balance sheet when the Entity has a legal or constructive obligation as a result of a prior event, and it is probable that future economic benefits will flow out of the Entity, and the value of the liability can be measured reliably.

On initial recognition, assets and liabilities are measured at cost. Measurement subsequent to initial recognition is effected as described below for each financial statement item.

Anticipated risks and losses that arise before the time of presentation of the annual report and that confirm or invalidate affairs and conditions existing at the balance sheet date are considered at recognition and measurement.

Income is recognised in the income statement when earned, whereas costs are recognised by the amounts attributable to this financial year.

Translation policies

Presentation currency

The financial statements are presented in Euro (EUR).

Foreign currency translation

On initial recognition, transactions denominated in foreign currencies are translated at the exchange rates at the

Accounting Policies

transaction date. Foreign exchange differences arising between the exchange rates at the transaction date and the date of payment are recognised in the income statement as financial income or financial expenses.

Receivables, payables, and other monetary items denominated in foreign currencies are translated at the exchange rates at the balance sheet date. The difference between the exchange rates at the balance sheet date and the date at which the receivable or payable arose or was recognised in the latest financial statements is recognised in the income statement as financial income or financial expenses.

Fixed assets acquired in foreign currency are measured at the exchange rate at the transaction date.

Income statement

Research and development costs

The item includes research and development costs not satisfying the criteria for capitalisation. Research costs comprise salaries, patent costs, consultancy fees, clinical trial cost, etc.

Contractual costs to provide services related to clinical trial start-up activities are recognised ratably over the estimated start-up period.

Contractual costs to provide services related to patient treatment are recognised based on data related to patient screening, enrollment and monitoring visits. Fixed fees not directly correlated to patient activities, such as CRO, management fees or database maintenance, are often recognised ratably over the treatment period.

Contractual costs to provide wrap-up activities are often recognised ratably over the estimated wrap-up period.

The company will receive charges from subsidiaries as a part of the service delivered.

Administrative expenses

Administrative expenses include expenses incurred in the year for company management and administration, including expenses relating to administrative staff, Management, office premises, lawyers, auditors, consultants etc. and expenses as well as amortisation/depreciation of assets used for administrative purposes.

Other operating income

Other operating income comprise items of a secondary nature relative to the Company's core activities, including public grants, gains or losses on the sale of fixed assets.

Public grants to cover expenses are recognised in the income statement when it is deemed likely that all grant criteria have been met. Grants which must be repaid under certain circumstances are recognised only where they are not expected to be repaid.

Other financial income

Other financial income comprises bank interest, realized - and unrealized exchange rates gains.

Other financial expenses

Other financial expenses are recognised in the income statements at the amounts that concern the financial year.

Tax on profit/loss for the year

Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.

Tax of the year includes tax credits for costs incurred in connection with research and development activities under the Danish Tax Regime.

Accounting Policies

Balance sheet

Intellectual property rights

Intangible assets acquired intangible rights.

Intangible assets are measured at cost less accumulated amortisation and impairment losses. Intellectual property rights etc are written down to the lower of recoverable amount and carrying amount.

Amortisation is made over the estimated economic life without the determination of a residual value.

The expected useful lives of the intangible assets are as follows:

Acquired intangible rights	10-16 years
----------------------------	-------------

The expected useful lives above 10 years are based on patents applications.

Property, plant and equipment

Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Art is measured at cost without depreciation.

Other fixtures and fittings, tools and equipment	3-5 years
--	-----------

Cost includes the acquisition price and costs directly related to them acquisition until the time at which the asset is ready for use.

Investments in group enterprises

Investments in group enterprises are measured at cost. Investments are written down to the lower of recoverable amount and carrying amount.

Leases (Company as lessee)

The Company has chosen IAS 17 Leases as interpretation for classification and recognition of leases.

On initial recognition, leases for assets that transfer substantially all the risks and rewards incident to ownership to the Company (finance leases) are measured in the balance sheet at the lower of fair value and the present value of future lease payments. In calculating the present value, the interest rate implicit in the lease or the incremental borrowing rate is used as the discount factor. Assets held under finance leases are subsequently accounted for as the Company's other assets.

The capitalised residual lease commitment is recognised in the balance sheet as a liability, and the interest element of the lease payment is recognised in the income statement over the term of the lease.

Leases that do not transfer substantially all the risks and rewards incident to ownership to the entity are operating leases. Payments relating to operating leases and any other leases are recognised in the income statement over the term of the lease. The Company's total liabilities relating to operating leases and other leases are disclosed under contingencies.

Impairment of fixed assets

The carrying amount of intangible assets and property, plant and equipment and equity investments in group entities is tested annually for indication of impairment other than the decrease in value reflected by amortisation/depreciation made.

Impairment tests are conducted on individual assets or cash-generating units when there is indication of impairment. Write-down is made to the lower of the recoverable amount and carrying amount.

The recoverable amount is the higher of the net selling price of an asset and its value in use. The value in use is calculated as the present value of the expected net cash flows from the use of the asset or the group of assets.

Accounting Policies

Receivables

Receivables are measured at amortised cost.

The Company has chosen IAS 39 as interpretation for impairment of financial receivables.

An impairment loss is recognised if there is objective evidence that a receivable or a group of receivables is impaired. If there is objective evidence that an individual receivable has been impaired, an impairment loss is recognised on an individual basis.

Tax payable or receivable

Current tax payables and receivables are recognised in the balance sheet as the estimated income tax charge for the year, adjusted for prior-year taxes and tax paid on account.

Deferred tax is measured using the balance sheet liability method on all temporary differences between the carrying amount and the tax value of assets and liabilities, with the exception of temporary differences occurring at the time of acquisition of assets and liabilities neither affecting the results of operations nor the taxable income.

Prepayments

Prepayments recognised under "Assets" comprise prepaid expenses regarding subsequent financial reporting years.

Cash

Cash comprises cash and short-term securities which are readily convertible into cash and subject only to minor risks of changes in value.

Equity

Contributed capital

The contributed capital comprises the nominal amount of the Company's shares.

Retained earnings

Retained earnings includes the accumulated profit/loss for the year and the reduction from any expenses directly attributable to capital increases.

Non paid in share capital

Non paid in share capital is presented according to the gross method whereby the non paid in share capital is recognised in equity and as a receivable under "Receivables from owners". An amount corresponding to the non paid in share capital is re classified from "Retained earnings" to "Reserve for non paid in capital.

Of the total capital increase of 60 mEUR in 2023, 75% of the capital increase is not paid as of 31/12 2023.

Other reserves

Other reserves comprise of amounts relating to the special reserve that has been established upon the execution of the share capital decrease in accordance with section §188 (1) (3) of the Danish Companies Act. The special fund may only be used after resolution of the general meeting.

Liabilities other than provisions

The Company has chosen IAS 39 as interpretation for recognition and measurement of liabilities.

Financial liabilities are recognised at the date of borrowing at the proceeds received less transaction costs paid. On subsequent recognition, financial liabilities are measured at amortised cost, corresponding to the capitalised value, using the effective interest rate. Accordingly, the difference between the proceeds and the nominal value is recognised in the income statement over the term of the loan.

Other liabilities are measured at net realisable value.

Income Statement

	Note	2023 EUR	2022 EUR
Gross profit		0	0
Research and development costs	1	-67.718.616	-46.512.144
Administrative expenses	1	-10.121.137	-16.388.058
Other operating income		15.709	54.607
Profit from ordinary operating activities		-77.824.044	-62.845.595
Other finance income	2	485.514	296.591
Finance expenses	3	-48.795	-421.658
Profit from ordinary activities before tax		-77.387.325	-62.970.662
Tax benefit (expense)	4	738.408	739.204
Profit (loss)		-76.648.917	-62.231.458
Proposed distribution of results			
Retained earnings		-76.648.917	-62.231.458
Distribution of profit (loss)		-76.648.917	-62.231.458

Balance Sheet as of 31 December

	Note	2023 EUR	2022 EUR
Assets			
Acquired intangible assets		1.674.587	1.827.940
Intangible assets	5	1.674.587	1.827.940
Fixtures, fittings, tools and equipment	6	336.377	159.725
Property, plant and equipment		336.377	159.725
Investments in group enterprises		97	97
Deposits		80.804	77.087
Financial assets	7	80.901	77.184
Fixed assets		2.091.865	2.064.849
Receivables from group enterprises		846.348	2.224.353
Receivables from owners	8	45.000.000	0
Tax receivables		737.902	737.996
Other receivables		288.549	690.710
Deferred income		576.211	1.984.282
Receivables		47.449.010	5.637.341
Cash and cash equivalents		9.498.040	48.255.007
Total non-fixed assets		56.947.050	53.892.348
Assets		59.038.915	55.957.197

Balance Sheet as of 31 December

	Note	2023 EUR	2022 EUR
Liabilities and equity			
Contributed capital		313.120	246.030
Other statutory reserves		327.297	327.297
Retained earnings		-27.386.647	34.279.042
Unpaid contributed capital	8	44.949.682	0
Equity		18.203.452	34.852.369
Trade payables		8.903.958	5.937.191
Payables to group enterprises		30.558.204	14.600.969
Other payables		1.373.301	553.134
Deferred income, liabilities		0	13.534
Current liabilities		40.835.463	21.104.828
Liabilities		40.835.463	21.104.828
Liabilities and equity		59.038.915	55.957.197
Financing and the going concern assumption	9		
Significant events occurring after end of reporting period	10		
Contingent liabilities	11, 12		
Deferred tax assets and liabilities	13		
Related parties	14		

Statement of changes in Equity

EUR

	Contributed capital	Other reserves	Unpaid Retained capital	Retained earnings	Total
Equity 1 January 2023	246.030	327.297	0	34.279.042	34.852.369
Increase of capital	67.090	0	0	59.932.910	60.000.000
Other adjustments of equity	0	0	45.000.000	-45.000.000	0
Profit (loss)	0	0	0	-76.648.917	-76.648.917
Equity 31 December 2023	313.120	327.297	45.000.000	-27.436.965	18.203.452

Notes

	2023	2022
	EUR	EUR
1. Employee benefits expense		
Wages and salaries	4.612.326	2.126.546
Pension	606.716	587.043
Other employee expense	40.091	28.892
	5.259.133	2.742.481
<i>Employee benefits expense are allocated as follows in the income statement</i>		
Research and development costs	3.266.063	1.693.012
Administrative expenses	1.993.070	1.049.469
	5.259.133	2.742.481
Average number of employees	21	19
2. Other finance income		
Other finance income	485.514	296.591
	485.514	296.591
3. Finance expenses		
Other finance expenses	48.795	421.658
	48.795	421.658
4. Tax benefit (expense)		
Tax Expense	-738.408	-739.204
	-738.408	-739.204

Tax benefit for the year comprise tax credit for research and development expenditures in Denmark

5. Intangible assets

	Acquired intangible assets
Cost at the beginning of the year	2.052.969
Cost at the end of the year	2.052.969
Amortisation at the beginning of the year	-225.029
Amortisation for the year	-153.353
Amortisation at the end of the year	-378.382
Carrying amount at the end of the year	1.674.587

Notes

	2023 EUR	2022 EUR
6. Fixtures, fittings, tools and equipment		
Cost at the beginning of the year	183.753	183.753
Addition during the year, incl. improvements	232.429	0
Cost at the end of the year	416.182	183.753
Depreciation at the beginning of the year	-24.028	-16.911
Depreciation for the year	-55.777	-7.117
Depreciation at the end of the year	-79.805	-24.028
Carrying amount at the end of the year	336.377	159.725

7. Investments

	Investments in group enterprises	Deposits
Cost at the beginning of the year	97	77.087
Addition during the year	0	3.717
Cost at the end of the year	97	80.804
Carrying amount at the end of the year	97	80.804

8. Share capital

In September 2023, the parent company, IO Biotech, Inc. carried out a capital increase of nominal DKK 500.000 (EUR 67.204) with total proceeds of DKK 446.400.000 (EUR 60.000.000). Of the capital increase 25%, equivalent to nominal DKK 125.000 or proceeds of DKK 111.600.000 (EUR 15.000.000) have been paid in cash and 75%, equivalent to nominal DKK 375.000 or proceeds of DKK 334.800.000 (EUR 45.000.000) is non paid share capital. The non paid portion of the share capital must be paid upon demand by the Company's executive management.

In 2022, the Company's share capital was divided in to share classes comprising A-shares, B-shares, and C-shares. In 2023, the Company made decision to close and merge the share classes into one single share class and thereby simplify the company's equity structure.

9. Financing and the going concern assumption

The Company is financed via shareholder's equity and payables to group enterprises. The Company has received a letter of financial support from its sole shareholder, IO Biotech, Inc., wherein IO Biotech, Inc. guarantees to support the Company with sufficient liquidity, to finance the current investment program and planned operating losses at least through 30 June 2025.

On this basis, the financial statements are prepared on going concern assumption.

10. Significant events occurring after end of reporting period

No events have occurred after the balance sheet date to this date, which would influence the evaluation of the annual report.

Notes

2023	2022
EUR	EUR

11. Contingent liabilities

We enter into contracts in the ordinary course of business with third-party service providers for clinical trials, preclinical research studies and testing, manufacturing and other services and products for operating purposes. These contracts generally provide for termination upon notice of 30 to 90 days, and therefore, we believe that our non-cancelable obligations under these agreements are not material and we cannot reasonably estimate whether they will occur. However, in the event of a termination of any contracts with CROs or other institutions and with respect to active patients enrolled in our clinical trials, we may be financially obligated for a period beyond the contractual termination notice periods. We may also enter into additional research, 155 manufacturing, supplier, lease and other agreements in the future, which may require up-front payments and even long-term commitments of cash.

12. Liabilities under operational leases

Liabilities under rental or operational lease agreements until maturity	384.580	592.506
	<u>384.580</u>	<u>592.506</u>

13. Deferred tax assets

The Company has tax loss carry forward totalling EUR 204.9 million. The nominal value thereof is 22%, or EUR 45.1 million, which has not been recognised in the balance sheet due to uncertainty as to future utilization of the tax losses.

14. Related parties

Name and registered office of the Parent preparing consolidated financial statements for the largest group:
 IO Biotech Inc.
 Orange Street 1209
 DE 19801
 Wilmington
 USA

Information about consolidated financial statements:

The financial statements for 2023 for IO Biotech, Inc can be retrieved at :

<https://www.sec.gov/ix?doc=/Archives/edgar/data/1865494/000095017024026275/iobt-20231231.htm>